YangYChengJLiuCZhangXMaNZhouZet al
This import alert does not apply to GLP-1 API from manufacturers that, based on an FDA inspection or other FDA evaluation, appear to be in compliance with FDAs rigorous standards for manufacturing practices
At this point, there is no peer-reviewed evidence confirming its safety or effectiveness in humans
Substantial variability exists in analytical approaches, experimental models, particle characteristics, exposure metrics, and outcome measures across human, in vitro, and in vivo evidence streams, which necessitates cautious interpretation and precludes quantitative synthesis
SBIR Opportunities Funding Opportunities in Open Submission Open Period: April 15 to May 13, 2026 *Pre-Release (Q&A Only) was open from September 3 to September 23, 2025